Nurix Therapeutics Inc. (NRIX)
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NRIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.36B
- EPS (TTM)
- -$3.46
- Dividend yield
- None
- 52-week range
- 9.00 – 28.23
- Day range
- 22.18 – 23.10
- Volume / Avg
- 1.51M / 1.27M
- Beta
- —
- Shares outstanding
- 103.78M
- Next earnings
- Oct 8, 2026
52-week range
NRIX stock today
On Oct 7, NRIX ended the session at $22.73, adding $0.13 (0.58%), versus the S&P 500's 0.22% decline. Shares are 19.5% below their 52-week high of $28.23, set on Aug 19, 2026 and 152.6% above the 52-week low of $9.00, in the middle of the past year's range. NRIX is up 19.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 131.2%.
Nurix Therapeutics has posted a net loss over the last twelve months (EPS of -$3.46), so its P/E ratio is not meaningful. The company is scheduled to report Aug/2026 results on Oct 8; analysts expect EPS of -$0.56.
Summary generated from market data by MetaCap's automated system. Methodology
About Nurix Therapeutics
Company profileNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Arthur T. Sands M.D., Ph.D.
- Headquarters
- Brisbane, CA
- Employees
- 317
- IPO year
- 2020
- Website
- nurixtx.com
Analyst forecast
ForecastConsensus (14 analysts)
none
Avg. price target
$33.93+49.27%
- Strong buy 5
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 8, 2026
- EPS estimate
- $-0.56
Nurix Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs NRIX |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs NRIX |
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs NRIX |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs NRIX |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs NRIX |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs NRIX |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs NRIX |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs NRIX |
Indexes, lists and sector
Nurix Therapeutics stock FAQ
What is Nurix Therapeutics's stock price today?
NRIX last traded at $22.73 as of Oct 7, 4:00 PM EDT, up 0.58% on the day. Prices are delayed at least 15 minutes.
When is Nurix Therapeutics's next earnings date?
Nurix Therapeutics is expected to report earnings on Thursday, October 8, 2026. Analysts expect EPS of $-0.56.
Who is Nurix Therapeutics's CEO?
Dr. Arthur T. Sands M.D., Ph.D. is the chief executive officer of Nurix Therapeutics Inc., which has about 317 employees.
What is the NRIX 52-week high?
The 52-week high for NRIX is $28.23 and the 52-week low is $9.00. The stock is currently 19.5% below its high.